Michael J Mina1, Keith P Klugman2, Jason W Rosch3, Jonathan A McCullers3. 1. Medical Scientist Training Program, Emory University School of Medicine Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia Department of Infectious Diseases, St Jude Children's Research Hospital, Memphis, Tennessee. 2. Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia. 3. Department of Infectious Diseases, St Jude Children's Research Hospital, Memphis, Tennessee.
Abstract
BACKGROUND: Infection with influenza A virus (IAV) increases susceptibility to respiratory bacterial infections, resulting in increased bacterial carriage and complications such acute otitis media, pneumonia, bacteremia, and meningitis. Recently, vaccination with live attenuated influenza virus (LAIV) was reported to enhance subclinical bacterial colonization within the nasopharynx, similar to IAV. Although LAIV does not predispose to bacterial pneumonia, whether it may alter bacterial transmigration toward the middle ear, where it could have clinically relevant implications, has not been investigated. METHODS: BALB/c mice received LAIV or phosphate-buffered saline 1 or 7 days before or during pneumococcal colonization with either of 2 clinical isolates, 19F or 7F. Middle ear bacterial titers were monitored daily via in vivo imaging. RESULTS: LAIV increased bacterial transmigration to and persistence within the middle ear. When colonization followed LAIV inoculation, a minimum LAIV incubation period of 4 days was required before bacterial transmigration commenced. CONCLUSIONS: While LAIV vaccination is safe and effective at reducing IAV and coinfection with influenza virus and bacteria, LAIV may increase bacterial transmigration to the middle ear and could thus increase the risk of clinically relevant acute otitis media. These data warrant further investigations into interactions between live attenuated viruses and naturally colonizing bacterial pathogens.
BACKGROUND: Infection with influenza A virus (IAV) increases susceptibility to respiratory bacterial infections, resulting in increased bacterial carriage and complications such acute otitis media, pneumonia, bacteremia, and meningitis. Recently, vaccination with live attenuated influenza virus (LAIV) was reported to enhance subclinical bacterial colonization within the nasopharynx, similar to IAV. Although LAIV does not predispose to bacterial pneumonia, whether it may alter bacterial transmigration toward the middle ear, where it could have clinically relevant implications, has not been investigated. METHODS: BALB/c mice received LAIV or phosphate-buffered saline 1 or 7 days before or during pneumococcal colonization with either of 2 clinical isolates, 19F or 7F. Middle ear bacterial titers were monitored daily via in vivo imaging. RESULTS:LAIV increased bacterial transmigration to and persistence within the middle ear. When colonization followed LAIV inoculation, a minimum LAIV incubation period of 4 days was required before bacterial transmigration commenced. CONCLUSIONS: While LAIV vaccination is safe and effective at reducing IAV and coinfection with influenza virus and bacteria, LAIV may increase bacterial transmigration to the middle ear and could thus increase the risk of clinically relevant acute otitis media. These data warrant further investigations into interactions between live attenuated viruses and naturally colonizing bacterial pathogens.
Authors: Xing Cheng; James R Zengel; Amorsolo L Suguitan; Qi Xu; Weijia Wang; Jim Lin; Hong Jin Journal: J Infect Dis Date: 2013-05-08 Impact factor: 5.226
Authors: Robert B Belshe; Kathryn M Edwards; Timo Vesikari; Steven V Black; Robert E Walker; Micki Hultquist; George Kemble; Edward M Connor Journal: N Engl J Med Date: 2007-02-15 Impact factor: 91.245
Authors: Junhee Seok; H Shaw Warren; Alex G Cuenca; Michael N Mindrinos; Henry V Baker; Weihong Xu; Daniel R Richards; Grace P McDonald-Smith; Hong Gao; Laura Hennessy; Celeste C Finnerty; Cecilia M López; Shari Honari; Ernest E Moore; Joseph P Minei; Joseph Cuschieri; Paul E Bankey; Jeffrey L Johnson; Jason Sperry; Avery B Nathens; Timothy R Billiar; Michael A West; Marc G Jeschke; Matthew B Klein; Richard L Gamelli; Nicole S Gibran; Bernard H Brownstein; Carol Miller-Graziano; Steve E Calvano; Philip H Mason; J Perren Cobb; Laurence G Rahme; Stephen F Lowry; Ronald V Maier; Lyle L Moldawer; David N Herndon; Ronald W Davis; Wenzhong Xiao; Ronald G Tompkins Journal: Proc Natl Acad Sci U S A Date: 2013-02-11 Impact factor: 11.205
Authors: Hannah M Rowe; Victoria A Meliopoulos; Amy Iverson; Perrine Bomme; Stacey Schultz-Cherry; Jason W Rosch Journal: Nat Microbiol Date: 2019-05-20 Impact factor: 17.745
Authors: Amy Iverson; Christopher J Meyer; Peter Vogel; Samanthi Waidyarachchi; Nisha Das; David F Bruhn; Aaron Poole; Michelle M Butler; Terry L Bowlin; Richard E Lee; Jason W Rosch Journal: Antimicrob Agents Chemother Date: 2019-04-25 Impact factor: 5.191
Authors: Melinda M Pettigrew; Mark R Alderson; Lauren O Bakaletz; Stephen J Barenkamp; Anders P Hakansson; Kevin M Mason; Johanna Nokso-Koivisto; Janak Patel; Stephen I Pelton; Timothy F Murphy Journal: Otolaryngol Head Neck Surg Date: 2017-04 Impact factor: 3.497
Authors: Stephen J Barenkamp; Tasnee Chonmaitree; Anders P Hakansson; Terho Heikkinen; Samantha King; Johanna Nokso-Koivisto; Laura A Novotny; Janak A Patel; Melinda Pettigrew; W Edward Swords Journal: Otolaryngol Head Neck Surg Date: 2017-04 Impact factor: 3.497
Authors: Karina Mueller Brown; Valerie Le Sage; Andrea J French; Jennifer E Jones; Gabriella H Padovani; Annika J Avery; Stacey Schultz-Cherry; Jason W Rosch; N Luisa Hiller; Seema S Lakdawala Journal: FEMS Microbes Date: 2022-03-04